Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2026.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals reported strong FY26 results with consolidated revenue of Rs 632.63 crore, more than 58% growth from Rs 398.25 crore in FY25. Net profit after tax surged to Rs 121.53 crore, over double the Rs 58.34 crore earned in the previous year. The statutory auditor issued an unmodified (clean) opinion on both consolidated and standalone financials. The Board also noted the resignation of Company Secretary Vinay Kumar Mishra effective June 10, 2026, and appointed Sharp & Tannan Associates as internal auditor for FY27. During the year, the company acquired 75% stake in Apnar Pharma Private Limited and 51% membership in Zoraya Pharmaceuticals LLC.
The doubling of profits and clean audit signal strong operational performance. However, the departure of the compliance officer may raise governance concerns for some investors. The stock could see positive reaction given the robust earnings growth.